EA201991471A1 - Способы введения гепсидина - Google Patents

Способы введения гепсидина

Info

Publication number
EA201991471A1
EA201991471A1 EA201991471A EA201991471A EA201991471A1 EA 201991471 A1 EA201991471 A1 EA 201991471A1 EA 201991471 A EA201991471 A EA 201991471A EA 201991471 A EA201991471 A EA 201991471A EA 201991471 A1 EA201991471 A1 EA 201991471A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hepsidine
introduction
ways
hepcidin
decrease
Prior art date
Application number
EA201991471A
Other languages
English (en)
Inventor
Лакхмир Чавла
Джордж Тидмарш
Original Assignee
Ла Хойя Фармасьютикал Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ла Хойя Фармасьютикал Компани filed Critical Ла Хойя Фармасьютикал Компани
Priority claimed from PCT/US2017/067400 external-priority patent/WO2018118979A1/en
Publication of EA201991471A1 publication Critical patent/EA201991471A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к применению гепсидина в терапевтических способах для лечения различных состояний, при которых снижение концентрации сывороточного железа может быть полезным.
EA201991471A 2017-06-30 2017-12-19 Способы введения гепсидина EA201991471A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527354P 2017-06-30 2017-06-30
PCT/US2017/067400 WO2018118979A1 (en) 2016-12-19 2017-12-19 Methods of administering hepcidin

Publications (1)

Publication Number Publication Date
EA201991471A1 true EA201991471A1 (ru) 2020-01-28

Family

ID=69374483

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991471A EA201991471A1 (ru) 2017-06-30 2017-12-19 Способы введения гепсидина

Country Status (1)

Country Link
EA (1) EA201991471A1 (ru)

Similar Documents

Publication Publication Date Title
CL2015003731A1 (es) Inhibidores de bromodominios
PH12016500358A1 (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
EA201891366A1 (ru) Гуманизированные антитела против cd73
EA202091540A1 (ru) Антитела к lilrb2
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12018501443A1 (en) Methods of administering hepcidin
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201792227A1 (ru) Лечение рака легких ингибиторами глутаминазы
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
MX2017000306A (es) Metodos para tratar hipotension.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
ECSP18002725A (es) Agentes, usos y métodos para el tratamiento
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.